- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01813383
Clinical Relevance of Typing HLA-DR7-DQ2 (HLA)
March 14, 2013 updated by: Juan Francisco Delgado de la Poza, Corporacion Parc Tauli
Celiac disease patients with HLA-DR7-DQ2 haplotype have the same histological, analytical and clinical behaviour as patients with HLA-DR3-DQ2 haplotype.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Observational
Enrollment (Actual)
92
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Barcelona
-
Sabadell, Barcelona, Spain, 08208
- Corporacio Sanitaria i Universitaria Parc Tauli
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
No older than 18 years (ADULT, CHILD)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Probability Sample
Study Population
Celiac disease patients who have been diagnosed in a Hospital by a Pediatrician.
Description
Inclusion Criteria:
- Diagnosis of celiac disease following ESPGHAN recommendations
- HLA-DQ2 typing including HLA-DR3-DQ2 and HLA-DR7-DQ2 haplotypes
Exclusion Criteria:
- Patients who have not been diagnosed for celiac disease
- HLA-DQ2 typing that not include HLA-DR7-DQ2 haplotype
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
HLA-DR3-DQ2 patients
Patients with HLA-DR3-DQ2 haplotype
|
|
HLA-DR7-DQ2 patients
Patients with HLA-DR7-DQ2 haplotype
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Anti-tissue transglutaminase
Time Frame: Up to 1 month after diagnosis
|
Up to 1 month after diagnosis
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Anti-Endomysium autoantibodies
Time Frame: Up to 1 month after diagnosis
|
Up to 1 month after diagnosis
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Oberhuber histological damage classification
Time Frame: Up to 1 month after diagnosis
|
Up to 1 month after diagnosis
|
|
Clinical characteristics of celiac disease
Time Frame: Up to 1 month after diagnosis
|
Asymptomatic, intestinal symptoms, extra-intestinal symptoms, European Society for Pediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN) score
|
Up to 1 month after diagnosis
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Juan Francisco Delgado de la Poza, Immunology Section, Laboratori. UDIAT-CD. Corporació Sanitària i Universitària Parc Taulí
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2010
Primary Completion (ACTUAL)
December 1, 2012
Study Completion (ACTUAL)
March 1, 2013
Study Registration Dates
First Submitted
March 12, 2013
First Submitted That Met QC Criteria
March 14, 2013
First Posted (ESTIMATE)
March 19, 2013
Study Record Updates
Last Update Posted (ESTIMATE)
March 19, 2013
Last Update Submitted That Met QC Criteria
March 14, 2013
Last Verified
March 1, 2013
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Celiac disease and HLA-DQ2.2
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Celiac Disease Patients Following Recommendations of ESPGHAN
-
Healthpoint HospitalUnknownEvaluation of ASA Fasting Recommendations in Diabetic Patients
-
Guy's and St Thomas' NHS Foundation TrustKing's College London; University of Oxford; Engineering and Physical Sciences...CompletedMonitoring of Patients Following SurgeryUnited Kingdom
-
Medical Research Council of Southeast SwedenLinkoeping UniversityUnknownCounseling | Education of Patients | Problem-Based LearningSweden
-
University of TurkuCompletedUnidentified Gastrointestinal Symptoms Following Gluten-free Oats ConsumptionFinland
-
University of TurkuCompletedUnidentified Gastrointestinal Symptoms Following Gluten-free Oats ConsumptionFinland
-
Thomas Jefferson UniversityCompletedAdult Form of Celiac DiseaseUnited States
-
University Hospital, BordeauxRecruitingCardiac Rehabilitation Program Following the Management of ACS in Patients Presenting With SCADFrance
-
Federico II UniversityEnrolling by invitationPrevention of Clinical Symptoms in Celiac DiseaseItaly
-
University of Texas Southwestern Medical CenterWithdrawnPatients With a Diagnosis of Odynophonia
-
Tampere University HospitalTurku University Hospital; Kuopio University Hospital; Seinajoki Central Hospital and other collaboratorsEnrolling by invitationCeliac Disease | Diet, Gluten-Free | Celiac Disease in Children | Follow-up | Transition of CareFinland
Clinical Trials on There is not any intervention
-
TC Erciyes UniversityUnknownCoronary Artery Disease With Myocardial InfarctionTurkey
-
Hospital Universitario Marqués de ValdecillaGlaxoSmithKlineUnknown
-
Vance Thompson VisionAlcon ResearchCompletedPresbyopiaUnited States
-
Rambam Health Care CampusUnknownHodgkin Lymphoma Treated With Mediastinal IrradiationIsrael
-
National Taiwan University HospitalNational Taiwan University Tai-Chen Cell Therapy Center, Biomdcare CorporationRecruitingHematologic Diseases | Acute Leukemia | Artificial IntelligenceTaiwan
-
Shanghai Tongji Hospital, Tongji University School...Huashan HospitalCompleted
-
Linkoeping UniversityRecruiting
-
University of California, San FranciscoRecruitingMucopolysaccharidosis I | Mucopolysaccharidosis II | Mucopolysaccharidosis VI | Wolman Disease | Pompe Disease Infantile-Onset | Mucopolysaccharidosis IV A | Mucopolysaccharidosis VII | Neuronopathic Gaucher DiseaseUnited States
-
Stanford UniversityDuke University; National Institute of Environmental Health Sciences (NIEHS)CompletedPregnancy | Air PollutionUnited States
-
Northwell HealthWinterlight LabsCompletedSchizophrenia and Related DisordersUnited States